Canaccord Genuity analysts reiterated a Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on February 17, 2026. Alnylam Pharmaceuticals, Inc.
Canaccord Genuity analysts reiterated a Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on February 17, 2026.
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $332.61 with a market capitalization of $54.5B.
Current market data
NASDAQ · ALNY
$237.10
Up: +$4.22 · +1.78%
Live quote updated
Keep reading
analyst ·
analyst ·
analyst ·
sec_filing ·
